GLP-1 drugs affect reward circuits to reduce alcohol, opioid, and nicotine use. Key points GLP-1 drugs show potential to treat substance use disorders. These effects appear to be mediated at least in part through the modulation of reward pathways in the CNS. Early results show reductions in cravings, substance use, and other related outcomes. Glucagon-like peptide-1 (GLP-1) is a hormone responsible for most of the insulin release after consuming a meal. Its effects are mediat